These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Zhankuic Acids A, B and C from Teng YN; Wang YH; Wu TS; Hung HY; Hung CC Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31766413 [No Abstract] [Full Text] [Related]
8. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line. Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731 [TBL] [Abstract][Full Text] [Related]
9. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Liu J; Ye Z; Xiang M; Chang B; Cui J; Ji T; Zhao L; Li Q; Deng Y; Xu L; Wang G; Wang L; Wang Z Biomaterials; 2019 Dec; 223():119475. PubMed ID: 31520888 [TBL] [Abstract][Full Text] [Related]
10. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. Bihorel S; Camenisch G; Lemaire M; Scherrmann JM J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988 [TBL] [Abstract][Full Text] [Related]
11. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046 [TBL] [Abstract][Full Text] [Related]
12. Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance. Zhang Y; Zeng X; Wang H; Fan R; Hu Y; Hu X; Li J Drug Deliv; 2021 Dec; 28(1):670-679. PubMed ID: 33792436 [TBL] [Abstract][Full Text] [Related]
13. Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. Chen Y; Cheng Y; Zhao P; Zhang S; Li M; He C; Zhang X; Yang T; Yan R; Ye P; Ma X; Xiang G Int J Pharm; 2018 May; 542(1-2):266-279. PubMed ID: 29551747 [TBL] [Abstract][Full Text] [Related]
14. Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity. El-Sisi AE; Sokkar SS; Ibrahim HA; Hamed MF; Abu-Risha SE Fundam Clin Pharmacol; 2020 Aug; 34(4):458-475. PubMed ID: 32080901 [TBL] [Abstract][Full Text] [Related]
15. A hyaluronic acid modified cuprous metal-organic complex for reversing multidrug resistance via redox dyshomeostasis. Wan Y; Chen Z; Wang Y; Zhao W; Pei Z; Pu L; Lv Y; Li J; Li J; Pei Y Carbohydr Polym; 2023 Jul; 311():120762. PubMed ID: 37028879 [TBL] [Abstract][Full Text] [Related]
16. Overcoming Drug Resistance in Colon Cancer by Aptamer-Mediated Targeted Co-Delivery of Drug and siRNA Using Grapefruit-Derived Nanovectors. Yan W; Tao M; Jiang B; Yao M; Jun Y; Dai W; Tang Z; Gao Y; Zhang L; Chen X; Wang QL Cell Physiol Biochem; 2018; 50(1):79-91. PubMed ID: 30278432 [TBL] [Abstract][Full Text] [Related]
17. Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. El-Sisi AE; Sokar SS; Ibrahim HA; Abu-Risha SE Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1113-1129. PubMed ID: 31950222 [TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690 [TBL] [Abstract][Full Text] [Related]
19. Assessment of hyaluronic acid-modified imatinib mesylate cubosomes through CD44 targeted drug delivery in NDEA-induced hepatic carcinoma. Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh P; Tabassum H; Alka ; Singh S; Guleria A; Saraf SA Int J Pharm; 2022 Jun; 622():121848. PubMed ID: 35613653 [TBL] [Abstract][Full Text] [Related]
20. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V Colloids Surf B Biointerfaces; 2014 Nov; 123():600-9. PubMed ID: 25454761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]